Cyclophosphamide and Doxorubicin (CA x 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0--3 Positive Axillary Lymph Nodes: A Phase III Randomized Study
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride
compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3
positive axillary lymph nodes. Giving additional cancer treatment after surgery may help to
lower the risk that the cancer will come back (adjuvant therapy). Drugs used in
chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and paclitaxel, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. It is not yet known whether the
standard adjuvant therapy of cyclophosphamide and doxorubicin hydrochloride is more
effective than paclitaxel in treating women with breast cancer
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.